MIAMI, Oct. 21, 2021 /PRNewswire/ -- Big Cypress
Acquisition Corp. (NASDAQ: BCYP), (Big Cypress) a publicly-traded
special purpose acquisition company focused on innovative
biopharmaceutical firms, today announced that its stockholders have
approved the proposed business combination (the "Business
Combination") with SAB Biotherapeutics, Inc. (SAB), a
clinical-stage biopharmaceutical company developing a novel
immunotherapy platform producing targeted, high potency,
fully-human polyclonal antibody therapeutics and advancing programs
in infectious disease and immune system disorders, at a Special
Meeting of stockholders held on October 20,
2021 (the "Special Meeting").
Approximately 98.3% of the votes cast at the Special Meeting,
representing approximately 78.6% of Big Cypress' outstanding shares
of common stock entitled to vote at the Special Meeting, were cast
in favor of the proposal to approve the Business Combination. Big
Cypress' stockholders also voted in favor of all other proposals
presented at the Special Meeting. The formal results of the Special
Meeting will be included in a Current Report on Form 8-K to be
filed by Big Cypress with the Securities and Exchange Commission
(the "SEC").
The Business Combination is expected to close on or
about October 22, 2021, subject to the satisfaction or waiver
of customary closing conditions.
Upon closing of the Business Combination, the combined company
will be named SAB Biotherapeutics, Inc. (the "Combined Company")
and its common stock and warrants will be listed on the Nasdaq
Stock Market under the ticker symbols "SABS" and "SABSW",
respectively. The common stock and warrants of the Combined Company
are anticipated to begin trading on or about October 25, 2021.
Any outstanding units of Big Cypress, consisting of shares of Big
Cypress common stock and warrants to purchase Big Cypress common
stock, will automatically separate into the equivalent number of
common stock and warrants of the Combined Company upon the
consummation of the Business Combination.
"Our initial enthusiasm for the potential of SAB's
first-in-class, targeted fully-human polyclonal antibodies to offer
novel treatments for a wide range of diseases with significant
unmet medical needs has grown as the company has made significant
strides and we've worked closely together over the past months,"
said Samuel Reich, CEO of Big
Cypress and future Executive Chairman of the SAB Board of
Directors. "I am delighted that Big Cypress shareholders have
overwhelmingly ratified the business combination and I look forward
to the opportunity to contribute to SAB's future growth."
"We joined forces with Big Cypress because we believed their
experienced biopharmaceutical team truly appreciated the
differentiation and potential of our unique immunotherapy platform
and pipeline programs," said Eddie J.
Sullivan, PhD, co-founder, President and CEO of SAB. "Since
the merger was announced in June, our team has continued to execute
on all fronts. SAB has initiated a Phase 2 clinical trial in
seasonal influenza, initiated a Phase 3 adaptive trial for
COVID-19, announced new nonclinical data showing that our COVID-19
candidate effectively neutralizes emerging variants, including the
Delta variant, and has been awarded an additional $60.5 million in US government funding and built
out significant infrastructure. We are pleased that Big Cypress
shareholders recognized our progress and promise by approving this
business combination, as we embark upon this exciting next stage of
our growth."
About Big Cypress Acquisition Corp.
Big Cypress
Acquisition Corp. is a blank check company formed for the purpose
of effecting a merger, share exchange, asset acquisition, share
purchase, reorganization, or similar business combination with one
or more businesses with a focus within the life sciences industry.
Big Cypress is led by Chief Executive Officer, Chief Financial
Officer and Director Samuel J.
Reich. For more information, visit
www.bigcypressaccorp.com.
About SAB Biotherapeutics, Inc.
SAB Biotherapeutics,
Inc. (SAB) is a clinical-stage, biopharmaceutical company advancing
a new class of immunotherapies leveraging fully human polyclonal
antibodies. SAB has applied advanced genetic engineering and
antibody science to develop transchromosomic (Tc) Bovine™ herds
that produce fully human antibodies targeted at specific diseases,
including infectious diseases such as COVID-19 and influenza,
immune system disorders including type 1 diabetes and organ
transplantation, and cancer. SAB's versatile DiversitAb™ platform
is applicable to a wide range of serious unmet needs in human
diseases. It produces natural, specifically targeted, high-potency,
human polyclonal immunotherapies. SAB is currently advancing
multiple clinical programs and has collaborations with the US
government and global pharmaceutical companies. For more
information on SAB, visit: https://www.sabbiotherapeutics.com and
follow @SABBantibody on Twitter.
Forward-Looking Statements
Certain statements made
herein that are not historical facts are forward-looking statements
for purposes of the safe harbor provisions under The Private
Securities Litigation Reform Act of 1995. Forward-looking
statements generally are accompanied by words such as "believe,"
"may," "will," "estimate," "continue," "anticipate," "intend,"
"expect," "should," "would," "plan," "predict," "potential,"
"seem," "seek," "future," "outlook" and similar expressions that
predict or indicate future events or trends or that are not
statements of historical matters. These forward-looking statements
include, but are not limited to, statements regarding future
events, the development of SAB-185, and the proposed business
combination between Big Cypress and SAB. These statements are based
on the current expectations of SAB and are not predictions of
actual performance. These forward-looking statements are provided
for illustrative purposes only and are not intended to serve as,
and must not be relied on, by any investor as a guarantee, an
assurance, a prediction or a definitive statement of fact or
probability. Actual events and circumstances are difficult or
impossible to predict, will differ from assumption and are beyond
the control of Big Cypress or SAB.
Additional Information and Where to Find It
In
connection with the business combination, Big Cypress has filed
with the SEC a definitive proxy statement/prospectus. Big Cypress
commenced mailing of the definitive proxy statement/prospectus to
its stockholders on September 23,
2021. A proxy statement/prospectus has been sent to all Big
Cypress stockholders as of the record date of September 17, 2021. On October 20, 2021, the stockholders of Big Cypress
voted in favor of a proposal to approve the Business Combination at
the special meeting of stockholders. This communication is not a
substitute for the Registration Statement, the definitive proxy
statement/final prospectus or any other document that Big Cypress
sends to its stockholders in connection with the proposed business
combination. Investors and security holders of Big Cypress are
advised to read the proxy statement/prospectus in connection with
Big Cypress' solicitation of proxies for its special meeting of
stockholders to be held to approve the proposed business
combination (and related matters) because the proxy
statement/prospectus contains important information about the
proposed business combination and the parties to the proposed
business combination. Investors and security holders of Big Cypress
are also invited to review the results of the special meeting which
will be set forth in a Current Report on Form 8-K to be filed by
Big Cypress with the SEC. Stockholders will also be able to obtain
copies of the proxy statement/prospectus, without charge at the
SEC's website https://www.sec.gov/ or by directing a request
to ir@bigcypressaccorp.com.
Participants in the Solicitation
Big Cypress,
SAB and their respective directors, executive officers, other
members of management, and employees, under SEC rules, may be
deemed to be participants in the solicitation of proxies of Big
Cypress' stockholders in connection with the proposed business
combination. Investors and security holders may obtain more
detailed information regarding the names and interests in the
proposed business combination of Big Cypress' directors and
officers in Big Cypress' filings with the SEC including the
Registration Statement that has been submitted to the SEC by Big
Cypress, which includes the proxy statement of Big Cypress for the
proposed business combination, and such information and names of
SAB's directors and executive officers.
Non-Solicitation
This press release is not a proxy
statement or solicitation of a proxy, consent or authorization with
respect to any securities or in respect of the potential
transaction and shall not constitute an offer to sell or a
solicitation of an offer to buy the securities of Big Cypress or
SAB, nor shall there be any sale of any such securities in any
state or jurisdiction in which such offer, solicitation or sale
would be unlawful prior to registration or qualification under the
securities laws of such state or jurisdiction. No offer of
securities shall be made except by means of a prospectus meeting
the requirements of the Securities Act of 1933, as amended.
Contact:
Big Cypress Acquisition Corp.
Barbara Lindheim
BLL Partners for Big Cypress
+1 917-355-9234
blindheim@bllbiopartners.com
SAB Biotherapeutics. Inc.
Melissa Ullerich
+1 605-679-4609
mullerich@sabbiotherapeutics.com
View original
content:https://www.prnewswire.com/news-releases/big-cypress-acquisition-corp-stockholders-approve-business-combination-with-sab-biotherapeutics-301405381.html
SOURCE Big Cypress Acquisition Corp.